Alterity Therapeutics (PRNAD) Share-based Compensation (2017 - 2020)

Alterity Therapeutics (PRNAD) has reported Share-based Compensation for 4 consecutive years, with -$7875.5 the latest figure, recorded in Q2 2020.

• In Q2 2020, Share-based Compensation fell 112.61% year-over-year to -$7875.5; the TTM figure through Jun 2020 stood at $3611.4 (up 103.18% YoY), while the FY2025 annual figure was $627573.3, up 7.97% from the prior year.
• Share-based Compensation came in at -$7875.5 for Q2 2020 at Alterity Therapeutics, down from $62438.7 in the prior quarter.
• The five-year high for Share-based Compensation was $62438.7 in Q2 2019, with the low at -$124886.5 in Q4 2017.
• Average Share-based Compensation over 4 years is -$17150.1, with a median of -$1043.8 recorded in 2020.
• Across the five-year window, Share-based Compensation jumped 978.79% in 2019 and plunged 112.61% in 2020, its largest moves.
• Year by year, Share-based Compensation stood at -$124886.5 in 2017, then surged by 54.57% to -$56739.6 in 2018, then jumped by 210.04% to $62438.7 in 2019, then tumbled by 112.61% to -$7875.5 in 2020.
• According to Business Quant data, Share-based Compensation over the past three periods registered -$7875.5, $62438.7, and -$56739.6 for Q2 2020, Q2 2019, and Q4 2018 respectively.